Department of Gynaecology and Obstetrics, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China (mainland).
The First Clinical Medical School, Nanchang University, Nanchang, Jiangxi, China (mainland).
Med Sci Monit. 2021 May 24;27:e932146. doi: 10.12659/MSM.932146.
BACKGROUND Programmed death-1 and its ligand-1 (PD-1/PD-L1) regulate tumor immunotherapy. A large number of studies have explored the relationship between PD-1, PD-L1, and different tumor susceptibility. However, these conclusions are not always consistent. Therefore, we updated this meta-analysis. MATERIAL AND METHODS MEDLINE, Web of Science, EMBASE and other databases were searched systematically to obtain related research. Then, we used STATA15.0 software to carry out the final meta-analysis. The computational advantage is better than OR to evaluate this relationship. RESULTS A total of a total of 28 related studies were involved in our meta-analysis. It was found that PD-1 rs11568821 and rs7421861 increased the overall cancer probability in the allelic genetic model, while PD-1 rs36084323 effectively reduced the risk of cancer in the dominant genetic model. In the homozygous genetic model, PD-L1 rs17718883 effectively increased the probability of tumorigenesis. PD-L1rs4143815 is associated with a reduced incidence of cancer in heterozygote, homozygote and dominant genetic patterns. Subgroup analysis showed that PD-1rs2227981 can promote the susceptibility to breast cancer, while PD-1rs2227982 can reduce the susceptibility to breast cancer. PD-L1 rs2890658 can significantly reduce the risk of lung and liver cancer. CONCLUSIONS PD-1rs11568821, rs36084323, rs7421861, pD-L1rs17718883, and rs4143815 are associated with tumor susceptibility. However, a review based on more experimental evidence is needed to verify our findings.
程序性死亡受体 1 及其配体-1（PD-1/PD-L1）调节肿瘤免疫治疗。大量研究探索了 PD-1、PD-L1 与不同肿瘤易感性之间的关系。然而，这些结论并不总是一致的。因此，我们更新了这项荟萃分析。
系统检索 MEDLINE、Web of Science、EMBASE 等数据库，获取相关研究。然后，我们使用 STATA15.0 软件进行最终的荟萃分析。计算优势优于 OR 来评估这种关系。
共有 28 项相关研究纳入本荟萃分析。结果发现，PD-1 rs11568821 和 rs7421861 等位基因遗传模型增加了总体癌症发生概率，而 PD-1 rs36084323 显性遗传模型有效降低了癌症风险。在纯合遗传模型中，PD-L1 rs17718883 有效增加了肿瘤发生的概率。PD-L1 rs4143815 与杂合子、纯合子和显性遗传模式下癌症发病率降低有关。亚组分析表明，PD-1 rs2227981 可促进乳腺癌易感性，而 PD-1 rs2227982 可降低乳腺癌易感性。PD-L1 rs2890658 可显著降低肺癌和肝癌的风险。
PD-1 rs11568821、rs36084323、rs7421861、pD-L1 rs17718883 和 rs4143815 与肿瘤易感性相关。然而，需要更多基于实验证据的综述来验证我们的发现。
